Mineralys Therapeutics, Inc.
Net SellingMLYS·US·🇺🇸 US
39%buys·61%sells
344 transactions$485.8MTotal buys·48 buys
$132.4MTotal sells·75 sells
2323 insiders
Last: Mar 31, 2026
| Date | Insider | Type | Value | |
|---|---|---|---|---|
| Apr 15, 26 | Rodman David Malcom | Sell | $176K | |
| Apr 13, 26 | Congleton Jon | Sell | $422K | |
| Apr 13, 26 | Rodman David Malcom | Exercise | - | |
| Apr 13, 26 | Rodman David Malcom | Exercise | - | |
| Apr 13, 26 | Rodman David Malcom | Exercise | - | |
| Apr 13, 26 | Rodman David Malcom | Sell | $373K | |
| Apr 13, 26 | Rodman David Malcom | Exercise | $59K | |
| Apr 13, 26 | Rodman David Malcom | Exercise | $36K | |
| Apr 13, 26 | Rodman David Malcom | Exercise | $7K | |
| Mar 31, 26 | Karydas Daphne | Exercise | - |
Congleton Jon (CEO) recently executed a sell of $422K in Mineralys Therapeutics, Inc. shares on April 13, 2026. Overall insider sentiment is bearish (61% sales).
Mineralys Therapeutics, Inc. (MLYS) has recorded 344 insider operations, including 48 open-market purchases ($485.8M), 75 sales ($132.4M) and 221 other operations (stock option exercises, grants, tax dispositions, donations). The insider sentiment is bearish (61% sales).
Insider activity at Mineralys Therapeutics, Inc. is sustained, with operations recorded in 9 of the last 12 months — a sign of regular regulatory filings.
Among the most active insiders are Congleton Jon (CEO), Levy Adam Scott (CFO) & Rodman David Malcom (C SUITE), with respectively 37, 40, 117 transactions.
Across all 353 recorded transactions, the breakdown by type is: exercise (148, 42%), sells (78, 22%), grant (65, 18%), buys (48, 14%), other (14, 4%).
Data sourced from regulatory filings (SEC Form 4, AMF, BaFin, FI, and other European authorities).
Mineralys Therapeutics, Inc. has recorded 344 insider operations in total, including 48 open-market purchases ($485.8M), 75 sales ($132.4M) and 221 other operations (stock option exercises, grants, tax dispositions, donations). The most recent transaction was recorded on March 31, 2026.
Insiders at Mineralys Therapeutics, Inc. are currently net sellers, with 39% purchases and 61% sales across all reported transactions. Total buy volume is $485.8M versus $132.4M in sales, indicating a bearish insider sentiment.
InsiderLens tracks 23 insiders at Mineralys Therapeutics, Inc. (MLYS). Congleton Jon (CEO, 37 tx), Levy Adam Scott (CFO, 40 tx), Rodman David Malcom (C SUITE, 117 tx). Data is sourced from mandatory regulatory filings for persons with access to privileged information.
The insider signal for MLYS is bearish, based on a 39% buy ratio across 123 buy and sell transactions reported to financial regulators. Transactions from C-suite executives (CEO, CFO) and board members are generally considered the most informative signals.
Insider trading data for Mineralys Therapeutics, Inc. comes from official regulatory filings: SEC Form 4 (United States), AMF (France), BaFin (Germany), FI (Sweden), and other European financial authorities. These filings are mandatory for directors, officers, and holders of more than 10% of a company's shares. InsiderLens aggregates and normalizes this data for analysis.